热门资讯> 正文

Genentech获得狼疮药物obinutuzumab批准

2025-10-21 05:57

The US FDA approved Gazyva (obinutuzumab), a lupus nephritis treatment from Roche-owned (OTCQX:RHHBY) Genentech.
Gazyva is given via infusion four times in the first year, followed by twice a year after that.
In a phase 3 study, 46.4% of patients on Gazyva and standard therapy achieved a complete renal response vs. 33.1% on standard therapy alone.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Gazyva

More on Roche Holding

Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon?
Roche Holding AG (RHHBY) Discusses On Pharma Day 2025 (Transcript)
Roche Holding AG (RHHBY) Special Call - Slideshow
Roche breast cancer drug improves survival of up to 62% in late-stage trial
Sanofi and Insmed among winners of EU drug recommendations this week

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。